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ANTI-IDIOTYPE MONOCLONAL ANTIBODY 
1A7 AND USE FOR THE TREATMENT OF 
MELANOMA AND SMALL CELL 
CARCINOMA 
TECHNICAL FIELD 
The present invention relates isolation of anti-idiotypic 
antibody 1A7 raised against anti-GDZmAb 1462a and its 
use for the treatment and detection of melanoma and small 
cell carcinoma. 
BACKGROUND 
Monoclonal antibody to the human ganglioside GD2 
antigen, and to other melanoma and small cell lung carci 
nomas are known. For example, U.S. Pat. No. 4,675,287 to 
Reisfeld et al. discloses a monoclonal antibody to the human 
ganglioside GD2 antigen. This antibody is reactive with 
melanoma and oat cell lung carcinoma cells. This mono 
clonal antibody is tolerated by the human immune system 
and thus human immune system does not remove this 
antibody by immunoactive mechanisms. lntemational 
Patent Publication WO 8600909 to Reisfeld, R. A. ct al is 
directed to a “Monoclonal antibody directed to human 
ganglioside GDZ.” This patent is the international patent 
publication related to U.S. Pat. No. 4,675,287 to Reisfeld et 
al. described above. More speci?cally, the publication dis 
closes a non-human, mammalian monoclonal receptor pro 
duced by a hybridoma formed by fusion of cells from a 
myeloma cell line and lymphocytes that produce antibodies 
that react with ganglioside GD2 from a mammal immunized 
with a ganglioside GDz-containing immunogen is disclosed. 
U.S. Pat. No. 4,693,966 to Houghton et al. discloses 
human monoclonal antibodies from lymphocytes of patients 
with malignant melanoma. The monoclonal antibodies of 
Houghton et al. speci?cally bind to antigens found on 
surfaces of renal, lung and breast cancer cells. The antibody 
also detects the cytoplasmic antigen expressed by cells of 
neuroectodermal origin, such as melanoma cells. 
U.S. Pat. No. 4,965,498 to Yamasaki et al. discloses a 
monoclonal antibody speci?c to a sugar chain containing an 
N-glycolylneuramine acid and has the ability to bind to at 
least N-glycolyl GM2 ganglioside. Page 1, lines 55—56 
acknowledges that monoclonal antibodies against human 
melanoma which react with glycolipids such as GD2 gan 
glioside are known. 
U.S. Pat. No. 5,305,559 to Nicolson et al. is directed to 
methods and compositions for the identi?cation of meta 
static human tumors. Monoclonal antibodies of this patent 
react with human tumor cells and are prepared against a 580 
kilodalton glycoprotein antigen gp580. Antibodies are spe 
ci?c for lung metastasis from breast tissue and are not 
reactive with melanoma tumors. 
U.S. Pat. No. 5,091,177 to Hellstrom et al. issued is 
directed to monoclonal antibodies which de?ne a glycolipid 
antigen associated with human non-small cell lung carcino 
mas. Activity with melanoma cells is not disclosed. The 
monoclonal antibody has an IgG2 isotope. 
U.S. Pat. No. 5,134,075 to Hellstrom et al. discloses a 
monoclonal antibody which binds strongly to a protein 
antigen associated with human tumors, including lung 
tumors as well as melanomas and sarcomas. The monoclonal 
antibody is of the subclass IgG2a. 
U.S. Pat. No. 5,240,833 to Nudelman et al. discloses 
monoclonal antibodies that bind to tumor-associated gan 
gliosides. The monoclonal antibodies have selected prefer 
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2 
ential reactivity to melanomas, ncuroblastomas and adeno 
carcinomas. They are anti-ganglioside antibodies with 
speci?c isotopes such as IgG3 and lgG2a. 
U.S. Pat. No. 5,242,824 to Hellstrom et al. discloses novel 
monoclonal antibodies reactive with a glycolipid cell mem 
brane antigen on the surface of human carcinomas. Mono 
clonal antibodies react with carcinomas of the lung, ovary 
and colon. They show no detectable reactivity with mela 
noma cells. 
U.S. Pat. No. 5,270,202 to Rayehaudhuri discloses a 
novel anti-idiotypic antibody lMelpg2 which is speci?c for 
melanoma cells. It can be used for the diagnosis and 
treatment of melanoma tumors. 
U.S. Pat. No. 5,208,146 to lrie discloses murine mono 
clonal anti-idiotypc antibodies raised against human mono 
clonal anti-ganglioside antibody known as L612. The mono 
clonal antibody is speci?c for melanoma cells. 
U.S. Pat. No. 4,904,596 to Hakomori discloses a hybri 
doma cell line and monoclonal antibody to fucoganglioside, 
6B, which is present in human colonic adenocarcinoma and 
lung carcinoma cells. 
U.S. Pat. No. 5,009,995 to Albino et al. discloses mono 
clonal antibodies recognized by gpl30 antigen of human 
cells. The monoclonal antibodies are useful in the detection 
of the gpl30 antigen and human cells, including melanoma 
cells, which contain the antigen. 
U.S. Pat. No. 4,918,164 to Hellstrom et al. discloses 
anti-idiotypic antibodies for immunization against tumor, 
for inhibition of immune suppression mediated by suppres 
sor T cells or suppressor factors expressing an anti-idiotype 
against tumors bearing the oncofetal antigen. Monoclonal 
antibody recognizes a human melanoma associated GD3 
ganglioside antigen. 
Journal of Immunology, Volume 150, 142A, 1993 dis 
closes an abstract of Chatterjee et al. entitled “Syngeneic 
Monoclonal Anti-IdiotypeAntibodies Against a Monoclonal 
Antibody to Human Melanoma-Associated Antigen.” The 
abstract generally discloses that the 1A7 antibody was 
isolated, but does not disclose a method of obtaining it or 
provide any of its particular properties or uses. 
Patent No. EP 280209 is directed to “Monoclonal anti 
bodies against melanoma-associated antigens, hybridoma 
cell lines producing these antibodies, and uses of the mono 
clonal antibodies”. This patent to Thurin et al. discloses 
hybridomas producing antibodies against ganglioside anti 
gens GD2 and GD3 which are non-reactive with other 
ganglioside antigens. 
None of the patents nor literature recognize an anti- _ 
idiotypic monoclonal antibody speci?c for melanoma and 
small cell carcinoma cells which is not tolerated by the 
human immune system. 
Neuroblastomas are highly malignant tumors occurring 
during infancy and early childhood. Except for Wilms’ 
tumor, they are the most common retroperitoneal tumors in 
children. Neuroblastomas arise most commonly in the adre 
nal medulla, but they may also develop in other sympathetic 
ganglia within the thorax or abdomen. These tumors metas 
tasize early with wide spread involvement of lymph nodes, 
liver, bone, lung and marrow. The prognosis is often good 
when the tumor is diagnosed prior to obvious metastasis, but 
with metastasis, prognosis is poor despite the extensive use 
of radical surgery, deep X-ray therapy, and chemotherapeu 
tie agents. 
Several antigenic determinants have recently been 
detected on neuroblastoma cells with monoclonal antibodies 
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(Mabs). See Seeger, Ann. Intern. Med, 97, 873 (1982); 
Wikstrand et al., Cancer Res., 42, 267(1982); Wikstrand et 
al., J. Neuroimmunlogy, 3, 43 (1982); Eisenbarth et al., Proc. 
Nat’l Acad. Sci. (USA), 76, 4913 (1979); Liao et al., Eur. J. 
Immunol, 11, 450 (1981); Seeger et al., Cancer Res., 4, 
2714 (1981); Kennett et al., Advances in Neuroblastoma 
Research, p. 209, Raven Press, New York (Evans ed.) 
(1980); Seeger et al., J. Immunol., 128, 983 (1982); Kems 
head et al., Pediatr. Res., 15, 1282 (1981). 
A panel of such antibodies has been reported to be helpful 
in the differential diagnosis of neuroblastoma and lympho 
blastic disorders, Kemshead et al., Pediatr. Res., supra; 
Kemshead et al., Lancet, I2 (1983). In these same studies, 
antibodies were used either in immunoperoxidase assays 
with tumor tissue sections or in direct immuno?uorescence 
assays to detect tumor cells in bone marrow aspirates. 
The effective use of Mabs directed to any tumor-associ— 
ated antigens as diagnostic reagents depends on the quantity, 
expression and chemical nature of the corresponding anti 
gen. In this regard, Mabs directed to tumor-associated gan 
gliosides have been useful in de?ning antigens associated 
with melanoma, neuroblastoma, colon carcinoma, and 
adenocarcinoma, Hakomori et al., J. Natl. Cancer Inst., 
71,231 (1983). One of these antibodies was reported to 
detect a ganglioside antigen shed into the serum of patients 
with colon carcinomas, Koprowski et al., Science, 212, 53 
(1981). Some of the above neuroblastoma—associated anti 
gens are present in fetal neural tissues whereas others are 
expressed by both fetal and adult neural tissues. Seeger, Ann. 
Intern. Med., supra. 
Most of the monoclonal antibodies utilized to detect the 
neuroblastoma-associated antigens are not restricted in their 
reactivity to neuroectoderrnal tumors like melanoma and 
glioma but also recognize common antigens on other malig 
nancies such as a variety of sarcomas and leukemias, Seeger, 
Ann. Intern. Med., supra. In addition, only some of the 
antigenic structures on neuroblastoma cells recognized by 
monoclonal antibodies have been partially characterized by 
immunochemical means. Thus, a monoclonal antibody des 
ignated Mab 390 was reported to react with an antigenic 
determinant of human Thy-l that had a molecular weight of 
25,000 daltons. Seeger et al., J. Immunol., supra. 
Another Mab, designated A2 B5, was reported to recog 
nize a GD2 ganglioside on neurons, Eisenbarth et al., Proc. 
Nat’l Acad. Sci. (USA), supra. A human monoclonal anti 
body produced in vitro by a lymphoblast cell line from a 
melanoma patient was also reported to react with a GD2 
ganglioside present on neuroectoderm-derived tumors, 
Cahan et al., Proc. Nat’l Acad. Sci. (USA), 79, 7629 (1982). 
From a biological point of view, gangliosides are of 
considerable interest since they have been implicated in a 
variety of cellular functions, including cell-cell adhesion and 
communication, as well as cell-substrate interactions, Hako 
mori et al., J. Nat’l Cancer Inst., supra. Recent studies have 
emphasized the importance of gangliosides for tumor 
growth regulation by demonstrating di?erences in ganglio 
side composition among cells expressing various degrees of 
tumorigenicity, Itaya et al., Proc. Nat’l Acad. Sci. (USA), 73, 
1568 (1976). Consequently, the use of monoclonal antibod 
ies directed to ganglioside determinants aids in further 
delineating the role of gangliosides in these processes. 
Most of the monoclonal antibodies directed against neu 
roblastoma-associated antigens that have been reported thus 
far, Wikstrand et al., Cancer Res., supra; Wikstrand et al., J. 
Neuro-immunology, supra; Eisenbarth et al., Proc Nat’l 
Acad. Sci. (USA), supra, recognize a common antigenic 
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determinant on fetal tissues, especially fetal brain, as well as 
on adult brain and other neural tissues. In addition, cross 
reactions of such antibodies have also been reported with 
normal kidney, fibroblasts, rnyoblasts, and thymocytes, See 
ger et al., Cancer Res., supra, and Seeger et al., J. Immunol, 
supra, with islet cells, Eisenbarth et al., Proc. Nat’l Acad. 
Sci. (USA), supra, and with spleen cells, Wikstrand et al., 
Cancer Res., supra. 
Furthermore, some of the monoclonal antibodies reported 
in the literature are not only restricted in their reactivity to 
neuroectoderrnal tumors, such as neuroblastoma, melanoma 
and glioma, but also show binding to some forms of leuke 
mia, osteogenic sarcoma, rhabdomyosarcoma, leiomyosar 
coma and even to carcinomas of the lung and breast, Seeger, 
Ann. Intern. Med, supra. 
A monospeci?c human monoclonal antibody, (anti-OFA 
I-2), produced in vitro by a lymphoblast cell line that 
originated from a melanoma patient was reported to detect 
a GD2 ganglioside on human melanoma, glioma and neu 
roblastoma cells, while reportedly not reacting with a variety 
of cell lines derived from carcinomas and from diiferent 
lymphoid tumors, Cahan et al., Proc. Nat’l Acad. Sci. 
(USA), supra, and Irie et al., Proc. Nat’l Acad. Sci. (USA), 
79, 5666 (1982). However, problems have arisen when such 
a human monoclonal antibody is used for immunoperoxi 
dase assays of human tissues in that the anti-human second 
ary antibody required for such assays causes a large amount 
of non-speci?c background reactivity. 
Heterogeneity of neuroblastomas with regard to cell sur 
face antigenic expression has been reported in Seeger, Ann. 
Intern. Med, supra; Kemshead et al., Pediatr. Res., supra; 
Kemshead et al., Int. J. Cancer, 27, 447(1981); and, Kems 
head et al., Proc. Am. Assoc. Cancer Res., 2, 399 (1981). As 
discussed in these publications, Mab A2 B5 failed to react 
with some human neuroblastoma lines tested, and quantita 
tive differences in antigenic expression were observed 
between di?‘erent cell cultures. Analysis of tumor cells in 
heavily in?ltrated bone marrow aspirates indicated that only 
70 percent of the samples reacted with A2 B5, suggesting 
that the heterogeneity seen in the expression of antigen on 
cell lines is paralleled in fresh tumor material, Kemshead et 
al., Int. J. Cancer, supra. 
Thus there is a need in the art for new methods of 
detecting and treating melanoma and small cell carcinoma. 
The present invention overcomes the de?ciencies of the 
prior art by providing an anti-idiotypic antibody 1A7 raised 
against anti-GD2mAb l4G2a, which is not tolerated by the 
human immune system, and thus may be used as a vaccine 
to stimulate the immune system. This property of the present 
monoclonal antibody makes it ideal for a new immuno 
therapeutic approach to cancer. 
Disclosure of the Invention 
It is an object of the present invention to provide an 
anti-idiotype monoclonal antibody 1A7, which is the inter 
nal image of the GD2 ganglioside antigen which is highly 
expressed on malignant melanoma cell and small cell car 
cinoma cells. 
It is another object of the invention to provide an antibody 
which generates an active immunity to GD2 antigen which 
is highly expressed on malignant melanoma cell and small 
cell carcinoma cells. 
A further object of the invention is to provide a pharma 
ceutical composition comprising anti—idiotype monoclonal 
antibody 1A7, and a pharmaceutically acceptably carrier. 
5,612,030 
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A still further object of the invention provides a method 
of treatment of metastatic melanoma and small cell lung 
cancer comprising administering a pharmaceutically effec 
tive amount of a pharmaceutical composition of the inven 
tion to a patient in need of treatment. 
In a preferred embodiment the method may be adminis— 
tered to a patient who has had disease removed by surgery, 
radiation or chemotherapy and remains at high risk for 
recurrence of metastatic melanoma and small cell lung 
cancer. 
Another object of the invention is to provide a lA7 
monoclonal antibody which can be used as a substitute for 
GD2 antigen in all biochemical and serological assays, such 
as a monoclonal antibody probe. The 1A7 monoclonal 
antibody probe may be incorporated into a test kit in 
accordance with the present invention, such as a diagnostic 
test kit. 
The above and other objects of the invention will become 
readily apparent to those of skill in the relevant an from the 
following detailed description and ?gures, wherein only the 
preferred embodiments of the invention are shown and 
described, simply by way of illustration of the best mode of 
carrying out the invention. As is readily recognized the 
invention is capable of modi?cations within the skill of the 
relevant art without departing from the spirit and scope of 
the invention. 
BRIEF DESCRIPTION OF DRAWINGS 
FIG. 1 shows the binding of puri?ed Ab3 to Ab2 1A7 on 
the plate by sandwich radioimmunoassay. 
FIG. 2 demonstrates the inhibition of Abl-Ab2 binding 
by monkey Ab3 or vice-versa (Ab2—Ab3 binding inhibition) 
which shows that Abl and Ab2 share idiotopes and Ab3 is 
true anti-anti-idiotypic in nature. 
FIG. 3 shows the inhibition of binding of 1251 labelled 
l4G2a antibody to GD2 positive melanoma cell line M2l/P6 
in presence of different concentrations of Abl and Ab3. 
Parallel inhibition curves were obtained using either puri?ed 
Abl or Ab3 form monkey sera. This suggests that Abland 
Ab3 bind to the same epitope on GD2. 
FIG. 3A shows the inhibition of binding of I25 I-labelled 
14G2a antibody to puri?ed GD2 on the plate by Abl and 
Ab3. 
FIG. 4 shows the binding of Abl and Ab3 to different 
gangliosides on the plate by ELISA assay. 250 ng of GD2 
and other gangliosides were coated per well of 96-well 
microtiter plates, blocked and incubated with different con 
centrations of puri?ed Abl and Ab3. The bound antibody 
was detected using anti-Human-Ig-alkaline phosphatase 
labelled reagent and substrate. The CD. value obtained after 
2 hr. using 1.5 micrograms of different antibodies per well 
were plotted. At this concentration, there was only reactivity 
with GD2. 
FIG. 5 shows the ELISA results con?rmed by dot blot 
analysis. 
STATEMENT OF DEPOSIT 
A deposit of the hybridoma producing the 1A7 mono 
clonal antibody was made prior to the ?ling date of the 
above-identi?ed patent application under the terms of the 
Budapest Treaty with the American Type Culture Collection, 
Parklawn Drive, Rockville, Md., USA, Accession No. 
HB-ll786. 
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During the pendency of this application, access to the 
deposit will (a) be forwarded to one determined by the 
Commissioner to be entitled thereto; 
(b) all restrictions imposed by the depositor on the avail 
ability to the public of the deposited material will be 
irrevocably removed upon the granting of the patent, 
(c) the deposit will be maintained for a period of at least 
thirty years or at least ?ve years after the most recent request 
for the furnishings of a sample of the deposited material; and 
(d) the deposit will be replaced should it become neces 
sary due to inviability, contamination or loss of capability to 
function in the manner described in the speci?cation. 
DESCRIPTION OF THE INVENTION 
Anti-idiotype monoclonal antibody 1A7, is the internal 
image of a GD2 ganglioside antigen which is expressed on 
malignant melanoma cells and on small cell carcinoma cells. 
The anti-idiotype antibody 1A7, raised against a known 
anti-GD2 antibody (1462a), mimics GD2 antigen. However, 
it is not tolerated by the human immune system. This 
property of the present monoclonal anti-idiotype antibody 
makes it ideal for a new immuno-therapeutic approach to 
cancer. 
Discussion below represents the results of immunization 
and treatment of monkeys with anti-Id 1A7 (isotype IgGl-k) 
which mimics GD2. Murine monoclonal anti—Id 1A7 was 
raised against anti-GD2 mAb l4G2a (isotype IgG2a—k) 
obtained from Scripps Research Institute, La lolla. In pre 
vious studies of the inventors, small animals, such as mice 
and rabbits, were immunized three to four times bi-weekly 
with anti-Id 1A7 coupled to KLH and mixed with Freund’s 
Adjuvant. The production of anti-GD2 antibodies were 
induced in the animals. 
A murine monoclonal antibody mAB (IgGZak) which 
binds to the ganglioside GD2 in human melanoma, neuro 
blastoma, glioma and sarcoma has been used to generate 
monoclonal antibodies (Ab2) in BALB/c mice. The culture 
supernatants from primary fusion cells were initially 
screened by a sandwich radioimmunoassay using Id as 
antigen. 
Several Ab2 hybridomas were obtained that reacted with 
the immunizing Id of l4G2a (Abl) and did not react with 
any isotype or allotype matched control immunoglobulins. 
Three of the mAb2s reacted with the antigen binding site 
(paratope), since they inhibited the binding between 1251 
labelled 14G2a and the target melanoma cell line M21/P6. 
One of these clones lAI-lA7 is used to raise anti-anti 
idiotype antibodies (Ab3) in rabbits. Polyclonal rabbit A3 
sera competed with Abl for binding to M2l/P6 cell lines 
available from Scripps Institute, La Jolla, Calif, and inhib 
ited the binding of radiolabelled Abl to Ab2. 
The anti-idiotype monoclonal antibody to the anti-GD2 
antibody (designated 1462a) is designated 1A7. This anti 
Idiotype antibody is, therefore, the internal image of the 
GD2 ganglioside antigen which is highly expressed on 
malignant melanoma cell and small cell carcinoma cells. 
The anti-idiotype antibody mimics the GD2 ganglioside 
antigen. The present inventors have determined in mice, 
rabbits and monkeys, all acceptable experimental animal 
models, that when the anti-idiotype antibody is injected 
intraeutaneously into these animals that they develop an 
anti-anti-idiotype antibody that is like anti-GD2 and mimics 
the original anti-GD2 (l4G2a). 
A pair of male and female cynomolgus monkeys were 
immunized with 2 mg of 1A7 (intact IgGl) mixed with 100 
5,612,030 
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pg QS-2l (Cambridge Biotech), 3 to 4 times. Sera obtained 
from monkeys 2 weeks after 3rd and 4th immunizations 
were analyzed. 
Anti-anti-Id(Ab3) antibody from monkey sera was puri 
?ed ?rst by adsorption and then elution from a?inity column 
lA7-sepharose 4B and then by passing through a negative 
a?inity column of mouse IgG-sepharose 4B. The flow 
through material has been used as “puri?ed” Ab3 and 
compared with the reactivity of Abl (l4G2a) in different 
assays. 2.6 mg of puri?ed Ab3 was recovered from 10 ml of 
sera (i.e. about 260 micrograms Ab3 per ml of serum) from 
monkey #PRO 685 and #PRO 778. 
This anti-idiotype antibody can be used to treat patients 
with malignant melanoma and small cell lung cancer to 
generate an active immunity to the GD2 antigen which is 
highly expressed on their tumor cells. These patients are not 
capable in vivo of generating the active immunity to GD2, 
but by using the anti-idiotype as a surrogate antigen, they are 
able to overcome tolerance to this antigen and generate an 
active immunity to GD2 antigen. 
These new anti-idiotype antibodies represent a new 
immunotherapeutic approach to cancer. The antibodies may 
be used for the treatment and therapy of metastatic mela 
noma and small cell lung cancer. The antibodies may also be 
used as a prevention for recurrent disease in patients who 
have had disease removed by surgery, radiation or chemo 
therapy and who remain at high risk for recurrence. 
Production of Ab2 (1A7) 
The murine mAb l4G2a is an anti-GD2 antibody that 
mediates antibody-dependent cytotoxicity and complement 
mediated lysis of neuroblastoma and melanoma cell lines in 
vitro. Murine monoclonal antibody l4G2a (Abl) was used 
to immunize syngeneic BALB/c mice for the production of 
anti-idiotype antibody (Ab2). Six to eight weeks old female 
BALB/c mice were immunized four times over a period of 
two months. The ?rst injection was given i.p. and other 
injections i.p. and s.c., respectively. Mice were bled from 
time to time and sera were checked for anti-idiotype activity 
by radioimmuno assay using 14G2a and MClO (iso-allotype 
match control antibody) as plate coats. Three days before the 
fusion, mice were boosted intravenously with l4G2a in 
PBS. 
Fusion 
Fusion was done essentially following the method of Oi 
and Herzenberg, by using HAT sensitive mouse myeloma 
cell line P3-653 as a fusion partner and 50% PEG. The 
hybrids were selected by using HAT media. After screening 
for positive wells, the cells were cloned twice by limited 
dilution. 
Selection of anti-Idiotype antibody (Ab2) 
Initial screening of the hybridoma was done by sandwich 
RIA using 14G2a and MClO at a concentration of 500 ng per 
well as plate coats. After overnight incubation at 4° C., the 
plates were non—speci?cally blocked with 1% BSA in PBS 
for 1.5 hrs. Thereafter, 100 pl of undiluted hybridoma 
culture supernatant were incubated for 2 hrs. at room temp. 
After washing with PBS, the plates were incubated with 
125I-labeled 14G2a for 1.5 hrs. at room temp. with shaking. 
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Radioimmuno assay (RIA) 
Additional characterization of Ab2 was done by RIA. For 
the direct binding assay between Abl and Ab2, puri?ed Abl 
was used to coat plate (500 ng/well) and the binding of 
radiolabeled Ab2 to Abl was tested in the presence of 
different Abl, Ab2 or several control mouse myeloma pro 
terns. 
Anti-Idiotype assay 
To determine whether Ab2 recognizes the paratope of 
Abl, the following inhibition assays were done. Target 
tumor cells (M2l/P6) which contain GD2 antigen as a cell 
surface constituent, were grown as con?uent monolayer in 
96-well tissue culture plates. The binding of radiolabeled 
Abl to cultured cells was tested for inhibition in the presence 
of different Ab2 culture supernatant and also puri?ed Ab2 
preparation. 
Inhibition assay 
Percent inhibition of the assay was calculated according 
to the formula: 
%1nhrb1tion —l [—————RmaX_RC ] X 100 
in which R, is the average cpm of the experimental well with 
inhibitors, RC is the average background cpm and RMAX is 
the average maximum binding without any inhibitors. 
Puri?cation of Ab2 
To get enough puri?ed Ab2, ascites of Ab2 (1A7) hybri 
domas was prepared by injecting individual pristane primed 
BALB/c mice intraperitoneally with 2><l06 to lXlO7 viable 
hybrid cells. The IgGl fraction was isolated from ascites by 
chromatography on a Protein A-Sepharose CL 4B column. 
The purity of the isolated IgGl was checked by SDS-PAGE. 
Induction of anti-anti-idiotype antibodies (Ab3) by 
anti-Idiotype monoclonal antibody 1A7: 
Immunization of mice 
Eight weeks old BALB/c mice (5 in each group) were 
immunized with 100 pg of 1A7 coupled with KLH using 
glutaraldehyde to increase the immunogenicity in the syn— 
geneic mice. A total of 100 pg of Ab2 ~KLI-I were injected 
i.p. with Freund’s complete adjuvant. Two weeks later the 
mice were injected i.p. and s.c. with the same antigen dose 
mixed with incomplete Freund’s adjuvant. After 2 weeks 
rest, animals were boosted similarly at biweekly intervals. 
For semm antibody measurement, mice were bled every 
8—lO days after the last injection. The sera were assayed for 
anti-1A7 activity by sandwich radioimmuno assay, using 
500 ng of 1A7 per well as plate coat and anti-GD2 activity 
by ELISA and FACS analysis. 
Immunization of rabbits 
Adult New Zealand white rabbits were injected s.c. with 
500 ug of puri?ed Ab2-coupled to KLH, mixed with com 
plete Freund’s adjuvant at day 0. Rabbits were boosted at 
biweekly intervals with 500 pg of KLH coupled Ab2 mixed 
with incomplete Freund’s adjuvant. Rabbits were bled 7 
days after the last injection and the sera were checked for 
anti-Ab2 activity as well as anti GD2 activity. 
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Immunization of monkeys 
Cynomolgus monkeys (two per group, 2-4 kg weight) 
received four intramascular injections of puri?ed Ab2 (2 
mg) mixed with 100 pg of QS 21 as adjuvant. Control 
monkeys were immunized with unrelated Ab2, 11Dl0 
mixed with Q8 21 in the similar way. All injections were 
given at 2-week intervals. Monkeys were bled 10 days after 
each immunization. 
Puri?cation of Ab3 
Ab3 from immunized monkey sera was puri?ed using 
lA7-Sepharose 4B as chromatography column. Bound pro 
tein to the column was eluted by glycine-HCl, pH 2.7 and 
dialyzed against PBS. The dialyzed protein was then passed 
through a mouse lg coupled to Sepharose 48 column until 
it was completely depleted of anti-isotypic and anti-allotypic 
antibodies to murine lg. 
Characterization of Ab3 Sandwich Assay 
To check whether Ab3 can bind to Ab2, sandwich assay 
was done. Brie?y, 250 ng of Ab2 was coated in 96—well 
plates. After non-speci?c blocking with 1% BSA in PBS, 50 
pl of different concentration of puri?ed Ab3 from two 
monkeys sera was added and incubated for 2 hrs. at room 
temperature. After washing 125l-labeled Ab2 was added and 
incubated for 1.5 hrs. After washing, bound radioactivity 
was measured. 
Cell binding inhibition assay 
To determine whether Ab3 competes with Abl for binding 
to i) human melanoma cell line M2l/P6 or to ii) Ab2, the 
binding of radiolabeled l4G2a to M21/P6 cells or to Ab2 
was tested for inhibition in the presence of di?ferent dilutions 
of Ab3 and Abl preparations. Percent inhibition of the assays 
were calculated according to the formula described above. 
ELISA 
To measure anti-GD2 reactivity in the serum of immu 
nized mice, rabbit and monkeys, puri?ed GD2 (250 ng/well) 
was adsorbed to 96-well plates. After blocking wells with 
1% BSA in PBS, test serum and Abl were diluted in same 
buffer and added to wells and incubated overnight at room 
temp. After washing, the bound antibodies were detected 
using alkaline phosphatase labeled anti-mouse, anti-rabbit or 
anti—human lg reagents as second antibodies. 
In another experiment, different puri?ed gangliosides 
(250 ng/well) were coated in 96-well plates. After blocking, 
50 pl of different dilutions of monkey Ab3 and Abl were 
added to wells and incubated for 4 hrs. at room temp. Plates 
were washed and bound antibodies were detected using 
alkaline phosphatase-conjugated anti human lg as second 
antibodies. 
Dot Blot 
Reactivity of immunized sera and puri?ed Ab3 for anti 
GD2 antibodies against various gangliosides was also mea 
sured by immunoblotting. Puri?ed gangliosides (2 pg each 
of GM3, GM2, GMl, GD3, GD2 and GTlb) were spotted on 
strips of PVDF cellulose membrane at 1 cm intervals. After 
blocking with 3% BSA in PBS, the strips were incubated 
with puri?ed Ab3 or Abl (l 0 pg ml) overnight at room temp. 
After washing, the strips were incubated with alkaline 
phosphatase conjugated second antibody (1:1000 dilution) 
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for 2 hrs. at room temp. The strips were washed and 
developed with NET and BCIP reagents (Bio Rad). 
Binding of Ab3 to M2l/P6 cells was also independently 
analyzed by flow cytometry. Target cells M2l/P6 or control 
cells MOLT-4 (5X105 in PBS supplemented with 0.2% BSA) 
were incubated with different dilutions of Ab3 and Abl for 
2 hrs. with gentle shaking at 4° C. After washing with PBS, 
the staining was done with FITC labeled second antibody 
and analyzed on a FACScan flow cytometer. 
DETAILED DESCRIPTION OF THE FIGURES 
FIG. 1 shows a Sandwich assay: 250 ng of 1A7 (Ab2) was 
coated in 96-well plate. After blocking, 50 pl of different 
concentration of PRO #685 or PRO #778 (Ab3) was added 
and incubated 2 h at room temp with shaking. After washing, 
90000 cpm of radiolabeled 1A7 was added to each well and 
incubated 1.5 h at room temp. The plate was washed and 
bound radioactivity was measured. 
FIG. 2 shows an inhibition assay: 500 ng of 1A7 (Ab2) or 
l4G2a (Abl) was coated in 96-well plate. After blocking, 50 
pl of different concentrations of PRO #685 (Ab3) along with 
50 pl of radiolabeled l4G2a or 1A7 (90000 cpm) were added 
to each well. After 1.5 h incubation, plates were washed and 
bound radioactivity was counted. 
FIG. 3 shows a cell binding inhibition assay: 2><l06 
M21/P6 cells were incubated with different concentration of 
PRO #685, PRO #778 Ab3 and l4G2a in presence of 90000 
cpm of radiolabeled l4G2a for 2 hr with shaking. After 
washing, radioactivity bound to the cell pellet was counted. 
In FIG. 3A, 250 ng of GD2 was coated per well in 96 well 
plate. Different concentrations of Ab3 and Abl along with 
90,000 cpm of (lzsl-labeled) l4G2a were added. incubated 
2 hrs at room temperature with shaking, washed and 
counted. Percent inhibition was calculated and plotted 
against concentration of Abl and Ab3 used. 
FIG. 4 shows an ELISA assay: 250 ng of different 
gangliosides were coated in 96-well plate. After blocking, 50 
pl of different concentration of PRO #685 (Ab3) and l4G2a 
(Abl) were added and incubated 4 h at room temp. Bound 
antibody was detected using alkaline phosphatase conju 
gated second antibody. 
FIG. 5 shows a Dot Blot assay. 2 pg of di?ferent ganglio 
sides were coated on PVDF cellulose membrane strips and 
after blocking strips were incubated with either PRO #685 
(Ab3) or PRO #778 (Ab3) or l4G2a (Abl) or an unrelated 
monkey Ab3 which was raised against an unrelated Ab2, 
11Dl0 and PBS-BSA control, each antibody used as 10 
pg/ml, 5 ml of total solution. The incubation was done for 4 
hrs at room temp. with shaking. After washing, the strips 
were incubated with alkaline-phosphatase labeled 2nd anti 
body (1:1000 dil) for 2 hrs. at r.t., washed and developed. 
Pharmaceutical Formulation 
Further, the 1A7 monoclonal antibody of the present 
invention is useful in pharmaceutical compositions for sys 
temic administration to humans and animals in unit dosage 
forms, sterile parenteral solutions or suspensions, sterile 
non-parenteral solutions or suspensions oral solutions or 
suspensions, oil in water or water in oil emulsions and the 
like, containing suitable quantities of an active ingredient. 
Formulations for parenteral and nonparenteral drug delivery 
are known in the art as set forth in Reminglon’s Pharma 
ceutical Sciences, 18th Ed, Mack Publishing (1989) incor 
porated herein by reference in its entirety. 
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The compounds are useful in pharmaceutical composi 
tions (wt %) of the active ingredient with a carrier or vehicle 
in the composition in about 1 to 20% and preferably about 
5 to 15%. 
The above 1A7 monoclonal antibody can be present alone 
or in combination form with pharmaceutical carriers. The 
pharmaceutical carriers acceptable for the purpose of this 
invention are the art known carriers that do not adversely 
a?'ect the drug, the host, or the material comprising the drug 
delivery device. Suitable pharmaceutical carriers include 
sterile water; saline, dextrose; dextrose in water or saline; 
and the like. 
The effective dosage for mammals may vary due to such 
factors as age, weight, activity level or condition of the 
subject being treated. Typically, an effective dosage of a 
compound according to the present invention is about 2mg 
per injection in humans. A preferred dosage is 100 pg of 
Ab2-KLH (KLH=keyhole limpet hemocyanin) when 
injected i.p. with Freund’s complete adjuvant in small 
animals. A more preferred dosage range is 0.001 mg to 10 
mg of 1A7 (intact IgGl) mixed with QS-2l (Cambridge 
Biotech) in monkeys. 
Probe 
The 1A7 anti-idiotype monoclonal antibody according to 
invention may be labeled and used as a probe for the 
detection of melanoma or small cell carcinoma. The probes 
may be incorporated into a diagnostic test kit including a 
detectable label or marker for the probe. 
Diagnostic Kit 
The diagnostic kit may further comprise, where necessary, 
other components of the signal-producing system, including 
agents for reducing background interference, control 
reagents or an apparatus or container for conducting the test. 
Examples of imaging reagents that can be used include, 
but are not limited to, radiolabels such as 1311, 1111n, 1231, 
99mTc, 32P, 1251, 31-1, and 14C, ?uorescent labels such as 
?uorescein and rhodarnine, and cherniluminescers, such as 
luciferin. Other labels known to those of skill in the art are 
set forth in US. Pat. No. 4,366,241 and are incorporated 
herein by reference. The monoclonal antibody can be 
labeled with such reagents using techniques known in the 
art. For example, see Wensel and Meares, Radioimrnunoim 
aging and Radioimmunotherapy, Esevier, New York (1983), 
for techniques relating to the radiolabeling of proteins. (See 
also, Sambrook, M. J., Fritsch, E. F. & Marriatis, T. (1989) 
Molecular Cloning: A Laboratory Manual (Cold Spring 
Harbor Lab., Cold Spring Harbor, N.Y., section 10, incor 
porated herein by reference in its entirety). 
The purpose of the above description and examples is to 
illustrate some embodiments of the present invention with 
out implying any limitation. It will be apparent to those of 
skill in the art that various modi?cations and variations may 
be made to the composition and method of the present 
invention without departing from the spirit or scope of the 
invention. All patents and publications cited herein are 
incorporated by reference in their entireties. 
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We claim: 
1. An antibody having all the identifying characteristics of 
monoclonal antibody 1A7 produced by the hybridoma 
deposited under ATCC Accession No. HB—11786. 
2. Hybridoma designated 1 A7 having ATCC Accession 
No. HB-11786, or progeny thereof producing a monoclonal 
antibody having all the identifying characteristics of the 
antibody produced by said hybricloma 1A7. 
3. Monoclonal antibody produced by the hybridoma or 
the progeny thereof according to claim 2. 
4. Monoclonal antibody puri?ed from the hyb?doma or 
the progeny thereof according to claim 2. 
5. A puri?ed antibody having all the identifying charac 
teristics of an antibody produced by the hybridoma accord 
ing to claim 2. 
6. An antibody according to claim 1 wherein said antibody 
further comprises a detectable label. 
7. An antibody according to claim 6, wherein said detect 
able label is selected from the group consisting of radiola 
bels, fluorescent labels and chemiluminescent labels. 
8. A diagnostic test kit for detecting an anti-GD2 antibody 
m a biological sample, comprising an antibody according to 
claim 1 in a suitable container. 
9. The diagnostic kit of claim 8, wherein the antibody is 
capable of binding anti-GD2. 
10. The diagnostic kit of claim 8, wherein the antibody is 
labeled with a detectable label. 
11. The diagnostic kit of claim 8, wherein the detectable 
label is selected from the group consisting of radiolabels, 
?uorescent labels, and chemiluminescent labels. 
12. The diagnostic kit of claim 8, also comprising an 
anti-immunoglobulin reagent labeled with a detectable label. 
13. The diagnostic kit of claim 8, wherein the biological 
sample is obtained from an individual suspected of having a 
GD2 antigen associated cancer. 
14. The diagnostic kit of claim 8, wherein the sample is 
obtained from an individual suspected of having a cancer 
selected from the group consisting of melanoma, neuroblas 
toma, glioma, sarcoma, and small cell carcinoma. 
15. The diagnostic kit of claim 8, wherein the biological 
sample is obtained from an individual treated with an 
antibody according to claim 1. 
16. A method of preparing monoclonal antibody 1A7, 
comprising purifying antibody from the hybridoma or the 
progeny thereof of claim 2. 
17. A method of preparing monoclonal antibody 1A7, 
comprising growing the hybridoma or the progeny thereof of 
claim 2. 
18. A method for detecting an anti-GD2 antibody in a 
biological sample, comprising the steps of providing the 
diagnostic kit of claim 8, and contacting the antibody 
provided in the container with any anti-GD2 antibody in the 
biological sample. 
19. A method for eliciting active immunity to ganglioside 
GD2 in an individual, comprising administering to the 
individual the antibody of claim 1. 
20. The method of claim 19, wherein the active immunity 
comprises production of anti-GD2 antibody by the indi 
vidual. 
21. The method of claim 19, further comprising mixing 
the antibody with QS-21. 
